Fab Fragment of VHH-Based Antibody Netakimab: Crystal Structure and Modeling Interaction with Cytokine IL-17A
Open Access
Abstract
Interleukin 17A (IL-17A) is a proinflammatory cytokine produced by Th17 cells. Antibody BCD-085 (netakimab) against human IL-17A is one of the new inhibitors of this cytokine. In netakimab, the VH domain is replaced by the VHH domain of Lama glama possessing a long complementarity determining region (CDR-H3) in its heavy chain. Here we demonstrate the high affinity of IL-17A to the Fab fragment of netakimab and to its integral part, the VHH domain. We have determined the crystal structure of the Fab fragment of netakimab at 1.9 Å resolution. High variability in the orientation of light and heavy chains of the Fab fragment of netakimab was shown, which is determined by the peculiarity of the structural organization of the CDR-H3. As the high conformational plasticity of the molecule hampers modeling the Fab fragment of netakimab complexed to IL-17A, we have carried out modeling the complex between the antigen and the integral part of the Fab fragment, the VHH domain. We explain the high netakimab Fab fragment affinity for IL-17A by a large number of protein–protein contacts due to additional interactions between CDR-H3 and the cytokine dimer.Keywords
This publication has 36 references indexed in Scilit:
- IL-17 inhibitors for moderate-to-severe psoriasisSeminars in Cutaneous Medicine and Surgery, 2018
- IL-17 in Chronic Inflammation: From Discovery to TargetingTrends in Molecular Medicine, 2016
- In Vivo Neutralization of α-Cobratoxin with High-Affinity Llama Single-Domain Antibodies (VHHs) and a VHH-Fc AntibodyPLOS ONE, 2013
- Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH DomainsStructure, 2013
- Immunity to infection in IL‐17‐deficient mice and humansEuropean Journal of Immunology, 2012
- Strategies to Extend Plasma Half-Lives of Recombinant AntibodiesBioDrugs, 2009
- Ablynx Makes Nanobodies from Llama BodiesChemistry & Biology, 2006
- Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulinsVaccine, 2005
- Efficient Cancer Therapy with a Nanobody-Based ConjugateCancer Research, 2004
- Efficient tumor targeting by single‐domain antibody fragments of camelsInternational Journal of Cancer, 2002